PMID- 32148446
OWN - NLM
STAT- MEDLINE
DCOM- 20201214
LR  - 20201214
IS  - 1526-6702 (Electronic)
IS  - 0730-2347 (Print)
IS  - 0730-2347 (Linking)
VI  - 47
IP  - 1
DP  - 2020 Feb
TI  - Prognostic Value of 6-Minute Walk Distance in Patients Undergoing Percutaneous 
      Coronary Intervention: a Veterans Affairs Prospective Study.
PG  - 10-14
LID - 10.14503/THIJ-17-6471 [doi]
AB  - The 6-minute walk distance (6MWD) test is a useful prognostic tool in chronic 
      heart failure. Its usefulness after percutaneous coronary intervention is 
      unknown. In a prospective observational study, patients underwent a 6MWD test 
      within 2 weeks after percutaneous coronary intervention. The primary endpoint was 
      major adverse cardiovascular events (MACE) (death, acute coronary syndrome, and 
      heart failure admission) at one year. Receiver operating characteristic curves 
      and area under the curve were used to determine the 6MWD test's predictive power, 
      and the Youden index was used to measure its effectiveness. A total of 212 
      patients were enrolled (98% men; mean age, 65 +/- 9 yr). Major comorbidities were 
      hypertension in 187 patients (88%), dyslipidemia in 186 (88%), and diabetes 
      mellitus in 95 (45%). Among the 176 patients (83%) who completed the 6MWD test, 
      the incidence of MACE at one year was 22% (acute coronary syndrome in 17%; heart 
      failure admission in 4%; and death in 3%). The area under the curve for MACE was 
      0.59, and 6MWD was shorter for patients with MACE than for those without (290 vs 
      326 m; P=0.03). For 39 patients with previous heart failure who completed the 
      6MWD test, the area under the curve was 0.64 for MACE and 0.78 for heart failure 
      admission. The 6MWD test predicted reasonably well the incidence of MACE one year 
      after percutaneous coronary intervention. In a subgroup of patients with previous 
      heart failure, it fared even better in predicting heart failure admission. Larger 
      studies are needed to confirm these findings.
CI  - (c) 2020 by the Texas Heart(R) Institute, Houston.
FAU - Dasari, Tarun W
AU  - Dasari TW
FAU - Patel, Bhavin
AU  - Patel B
FAU - Wayangankar, Siddharth A
AU  - Wayangankar SA
FAU - Alexander, David
AU  - Alexander D
FAU - Zhao, Yan D
AU  - Zhao YD
FAU - Schlegel, JoAnn
AU  - Schlegel J
FAU - Leung, Cheuk
AU  - Leung C
FAU - Lozano, Pedro
AU  - Lozano P
FAU - Latif, Faisal
AU  - Latif F
FAU - Thadani, Udho
AU  - Thadani U
LA  - eng
GR  - U54 GM104938/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Observational Study
DEP - 20200201
PL  - United States
TA  - Tex Heart Inst J
JT  - Texas Heart Institute journal
JID - 8214622
SB  - IM
MH  - Aged
MH  - Coronary Artery Disease/diagnosis/mortality/physiopathology/*therapy
MH  - *Exercise Tolerance
MH  - Female
MH  - Functional Status
MH  - Heart Disease Risk Factors
MH  - Heart Failure/etiology/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Percutaneous Coronary Intervention/adverse effects
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - Recovery of Function
MH  - Risk Assessment
MH  - Time Factors
MH  - Treatment Outcome
MH  - United States
MH  - *United States Department of Veterans Affairs
MH  - *Walk Test
MH  - *Walking
PMC - PMC7046352
OTO - NOTNLM
OT  - Coronary artery disease/physiopathology/rehabilitation
OT  - exercise test/methods
OT  - heart failure/diagnosis/mortality/physiopathology
OT  - patient readmission
OT  - percutaneous coronary intervention
OT  - predictive value of tests
OT  - prospective studies
OT  - risk assessment/methods
OT  - walking
EDAT- 2020/03/10 06:00
MHDA- 2020/12/15 06:00
PMCR- 2020/02/01
CRDT- 2020/03/10 06:00
PHST- 2020/03/10 06:00 [entrez]
PHST- 2020/03/10 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/02/01 00:00 [pmc-release]
AID - 10.14503/THIJ-17-6471 [doi]
PST - epublish
SO  - Tex Heart Inst J. 2020 Feb 1;47(1):10-14. doi: 10.14503/THIJ-17-6471. eCollection 
      2020 Feb.